Projects per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Field of Science
- 3.1 Basic medicine
Fingerprint
Dive into the research topics where Viktorija Ulanova is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Projects
- 3 Finished
-
Pharmacogenomics of drug resistant tuberculosis
Ranka, R. (Project leader), Bandere, D. (Leading expert) & Ulanova, V. (Leading expert)
1/04/22 → 30/04/23
Project: RSU grants
-
Tuberculosis treatment: exploring the perspectives for personalized therapy
Bandere, D. (Project leader), Ulanova, V. (Assistant (student)), Vīksna, A. (Assistant (student)) & Sadovska, D. (Assistant (student))
1/01/21 → 31/12/23
Project: Fundamental and Applied Research Programme
-
Assessment of genetic factors in tuberculosis cases
Ranka, R. (Project leader), Ulanova, V. (Participant), Aļeiņikova, D. (Participant) & Freimane, L. (Participant)
1/09/20 → 31/08/21
Project: RSU grants
-
Effect of NAT2, GSTM1 and CYP2E1 genetic polymorphisms on plasma concentration of isoniazid and its metabolites in patients with tuberculosis, and the assessment of exposure-response relationships
Ulanova, V., Kivrane, A., Viksna, A., Pahirko, L., Freimane, L., Sadovska, D., Ozere, I., Cirule, A., Sevostjanovs, E., Grinberga, S., Bandere, D. & Ranka, R. (Corresponding Author), Mar 2024, In: Frontiers in Pharmacology. 15, 20 p., 1332752.Research output: Contribution to journal › Article › peer-review
Open AccessFile2 Citations (Scopus)12 Downloads (Pure) -
Exploring Variability in Rifampicin Plasma Exposure and Development of Anti-Tuberculosis Drug-Induced Liver Injury among Patients with Pulmonary Tuberculosis from the Pharmacogenetic Perspective
Kivrane, A. (Corresponding Author), Ulanova, V., Grinberga, S., Sevostjanovs, E., Viksna, A., Ozere, I., Bogdanova, I., Zolovs, M. & Ranka, R., 12 Mar 2024, In: Pharmaceutics. 16, 3, 388.Research output: Contribution to journal › Article › peer-review
Open AccessFile9 Downloads (Pure) -
Identification of factors determining patterns of serum CRP level reduction in response to anti-tuberculosis treatment initiation
Kivrane, A. (Corresponding Author), Ulanova, V., Grinberga, S., Sevostjanovs, E., Viksna, A., Bogdanova, I., Pahirko, L., Bandere, D. & Ranka, R., 11 Jun 2024. 2 p.Research output: Contribution to conference › Abstract
-
Unraveling tuberculosis patient cluster transmission chains: integrating WGS-based network with clinical and epidemiological insights
Sadovska, D. (Corresponding Author), Ozere, I., Pole, I., Ķimsis, J., Vaivode, A., Vīksna, A., Norvaiša, I., Bogdanova, I., Ulanova, V., Čapligina, V., Bandere, D. & Ranka, R., 2024, In: Frontiers in Public Health. 12, 1378426.Research output: Contribution to journal › Article › peer-review
Open AccessFile7 Downloads (Pure) -
Within-day variation of cell-free mitochondrial and nuclear DNA in blood plasma of patients with tuberculosis: associations with drug exposure and patient-related factors
Freimane, L., Ulanova, V., Kivrāne, A., Sadovska, D., Vīksna, A. & Ranka, R., 26 Jun 2024, In: FEBS Open Bio. 14, Suppl.2, p. 497 P-36-086.Research output: Contribution to journal › Meeting Abstract › peer-review
Open Access
-
Assessment of Rifampicin Exposure in Latvian Pulmonary Tuberculosis Patients in the Context with AADAC Genetic Polymorphisms
Kivrāne, A. (Speaker), Ulanova, V. (Co-author), Grinberga, S. (Co-author), Sevostjanovs, E. (Co-author), Vīksna, A. (Co-author), Pole, I. (Co-author), Ozere, I. (Co-author), Bogdanova, I. (Co-author), Zolovs, M. (Co-author), Bandere, D. (Co-author) & Ranka, R. (Co-author)
29 Mar 2023Activity: Talk or presentation types › Poster presentation
-
Mapping the potential of pharmaco-metabolomics for personalized antituberculosis therapy
Igumnova, V. (Speaker)
24 Mar 2021Activity: Talk or presentation types › Oral presentation